In patients treated with oral JAK inhibitors across various dermatologic indications, do you observe distinct differences in the incidence or severity of acneiform eruptions (JAKne) between specific agents, and how do you manage them?

According to a published meta-analysis, JAKne is most commonly induced by "combined JAK1 and JAK2 inhibitors, JAK1 inhibitors, as well as the TYK2 inhibitor deucravacitinib". Leading their list is abrocitinib (Cibinqo).

Martinez et al., PMID 37851459

As for treatment: "The encouraging news is that sta...